Literature DB >> 35500938

The Association of Excess Body Weight with Risk of ESKD Is Mediated Through Insulin Resistance, Hypertension, and Hyperuricemia.

Josef Fritz1, Wolfgang Brozek2, Hans Concin2, Gabriele Nagel2,3, Julia Kerschbaum4,5, Karl Lhotta6,7, Hanno Ulmer1, Emanuel Zitt8,6,7.   

Abstract

BACKGROUND: Insulin resistance, hypertension, hyperuricemia, and hypercholesterolemia are hypothesized to be important intermediates in the relationship between excess body weight and CKD risk. However, the magnitude of the total effect of excess body weight on ESKD mediated through these four pathways remains to be quantified.
METHODS: We applied a model for analysis of correlated mediators to population-based data from 100,269 Austrian individuals (mean age 46.4 years). Association of body mass index (BMI) was coalesced with ESKD risk into direct association. Indirect associations were mediated through the triglyceride-glucose (TyG) index (as an indicator of insulin resistance), mean arterial pressure (MAP), uric acid (UA), and total cholesterol (TC).
RESULTS: Mean follow-up was 23.1 years with 463 (0.5%) incident ESKD cases. An unhealthy metabolic profile (prevalence 32.4%) was associated with a markedly increased ESKD risk (multivariably adjusted hazard ratio (aHR), 3.57; 95% CI, 2.89 to 4.40), independent of BMI. A 5-kg/m2 higher BMI was associated with a 57% increased ESKD risk (aHRtotal association, 1.57; 1.38 to 1.77). Of this association, 99% (76% to 140%) arose from all mediators jointly; 33% (22% to 49%) through TyG index; 34% (24% to 50%) through MAP; 30% (21% to 45%) through UA; and 2% (-1% to 4%) through TC. The remaining direct association was nonsignificant (aHRdirect association, 1.01; 0.88 to 1.14).
CONCLUSIONS: TyG index, MAP, and UA, but not TC, mediate the association of BMI with ESKD in middle-aged adults. Our findings highlight that in addition to weight reduction, the control of metabolic risk factors might be essential in mitigating the adverse effects of BMI on kidney function.
Copyright © 2022 by the American Society of Nephrology.

Entities:  

Keywords:  blood pressure; body mass index; causal model; dialysis; end-stage kidney disease; insulin resistance; mediation; obesity; triglyceride-glucose index; uric acid

Mesh:

Substances:

Year:  2022        PMID: 35500938      PMCID: PMC9257805          DOI: 10.1681/ASN.2021091263

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   14.978


  70 in total

Review 1.  Insulin resistance, hyperinsulinemia, and hypertension: an epidemiologic approach.

Authors:  Pantelis A Sarafidis; George L Bakris
Journal:  J Cardiometab Syndr       Date:  2006

Review 2.  Uric acid and the cardio-renal effects of SGLT2 inhibitors.

Authors:  Clifford J Bailey
Journal:  Diabetes Obes Metab       Date:  2019-03-15       Impact factor: 6.577

3.  Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes.

Authors:  Alessandro Doria; Andrzej T Galecki; Cathie Spino; Rodica Pop-Busui; David Z Cherney; Ildiko Lingvay; Afshin Parsa; Peter Rossing; Ronald J Sigal; Maryam Afkarian; Ronnie Aronson; M Luiza Caramori; Jill P Crandall; Ian H de Boer; Thomas G Elliott; Allison B Goldfine; J Sonya Haw; Irl B Hirsch; Amy B Karger; David M Maahs; Janet B McGill; Mark E Molitch; Bruce A Perkins; Sarit Polsky; Marlon Pragnell; William N Robiner; Sylvia E Rosas; Peter Senior; Katherine R Tuttle; Guillermo E Umpierrez; Amisha Wallia; Ruth S Weinstock; Chunyi Wu; Michael Mauer
Journal:  N Engl J Med       Date:  2020-06-25       Impact factor: 91.245

Review 4.  Banting lecture 1988. Role of insulin resistance in human disease.

Authors:  G M Reaven
Journal:  Diabetes       Date:  1988-12       Impact factor: 9.461

5.  Body mass index and risk for end-stage renal disease.

Authors:  Chi-yuan Hsu; Charles E McCulloch; Carlos Iribarren; Jeanne Darbinian; Alan S Go
Journal:  Ann Intern Med       Date:  2006-01-03       Impact factor: 25.391

6.  Effect of Systolic and Diastolic Blood Pressure on Cardiovascular Outcomes.

Authors:  Alexander C Flint; Carol Conell; Xiushui Ren; Nader M Banki; Sheila L Chan; Vivek A Rao; Ronald B Melles; Deepak L Bhatt
Journal:  N Engl J Med       Date:  2019-07-18       Impact factor: 91.245

Review 7.  Obesity, kidney dysfunction and hypertension: mechanistic links.

Authors:  John E Hall; Jussara M do Carmo; Alexandre A da Silva; Zhen Wang; Michael E Hall
Journal:  Nat Rev Nephrol       Date:  2019-06       Impact factor: 28.314

8.  Regional variability in the incidence of end-stage renal disease: an epidemiological approach.

Authors:  Florian Wimmer; Wilhelm Oberaigner; Reinhard Kramar; Gert Mayer
Journal:  Nephrol Dial Transplant       Date:  2003-08       Impact factor: 5.992

9.  Metabolically Healthy Obesity and Risk of Kidney Function Decline.

Authors:  Alex R Chang; Aditya Surapaneni; H Lester Kirchner; Amanda Young; Holly J Kramer; David J Carey; Lawrence J Appel; Morgan E Grams
Journal:  Obesity (Silver Spring)       Date:  2018-03-02       Impact factor: 5.002

10.  Health Effects of Overweight and Obesity in 195 Countries over 25 Years.

Authors:  Ashkan Afshin; Mohammad H Forouzanfar; Marissa B Reitsma; Patrick Sur; Kara Estep; Alex Lee; Laurie Marczak; Ali H Mokdad; Maziar Moradi-Lakeh; Mohsen Naghavi; Joseph S Salama; Theo Vos; Kalkidan H Abate; Cristiana Abbafati; Muktar B Ahmed; Ziyad Al-Aly; Ala’a Alkerwi; Rajaa Al-Raddadi; Azmeraw T Amare; Alemayehu Amberbir; Adeladza K Amegah; Erfan Amini; Stephen M Amrock; Ranjit M Anjana; Johan Ärnlöv; Hamid Asayesh; Amitava Banerjee; Aleksandra Barac; Estifanos Baye; Derrick A Bennett; Addisu S Beyene; Sibhatu Biadgilign; Stan Biryukov; Espen Bjertness; Dube J Boneya; Ismael Campos-Nonato; Juan J Carrero; Pedro Cecilio; Kelly Cercy; Liliana G Ciobanu; Leslie Cornaby; Solomon A Damtew; Lalit Dandona; Rakhi Dandona; Samath D Dharmaratne; Bruce B Duncan; Babak Eshrati; Alireza Esteghamati; Valery L Feigin; João C Fernandes; Thomas Fürst; Tsegaye T Gebrehiwot; Audra Gold; Philimon N Gona; Atsushi Goto; Tesfa D Habtewold; Kokeb T Hadush; Nima Hafezi-Nejad; Simon I Hay; Masako Horino; Farhad Islami; Ritul Kamal; Amir Kasaeian; Srinivasa V Katikireddi; Andre P Kengne; Chandrasekharan N Kesavachandran; Yousef S Khader; Young-Ho Khang; Jagdish Khubchandani; Daniel Kim; Yun J Kim; Yohannes Kinfu; Soewarta Kosen; Tiffany Ku; Barthelemy Kuate Defo; G Anil Kumar; Heidi J Larson; Mall Leinsalu; Xiaofeng Liang; Stephen S Lim; Patrick Liu; Alan D Lopez; Rafael Lozano; Azeem Majeed; Reza Malekzadeh; Deborah C Malta; Mohsen Mazidi; Colm McAlinden; Stephen T McGarvey; Desalegn T Mengistu; George A Mensah; Gert B M Mensink; Haftay B Mezgebe; Erkin M Mirrakhimov; Ulrich O Mueller; Jean J Noubiap; Carla M Obermeyer; Felix A Ogbo; Mayowa O Owolabi; George C Patton; Farshad Pourmalek; Mostafa Qorbani; Anwar Rafay; Rajesh K Rai; Chhabi L Ranabhat; Nikolas Reinig; Saeid Safiri; Joshua A Salomon; Juan R Sanabria; Itamar S Santos; Benn Sartorius; Monika Sawhney; Josef Schmidhuber; Aletta E Schutte; Maria I Schmidt; Sadaf G Sepanlou; Moretza Shamsizadeh; Sara Sheikhbahaei; Min-Jeong Shin; Rahman Shiri; Ivy Shiue; Hirbo S Roba; Diego A S Silva; Jonathan I Silverberg; Jasvinder A Singh; Saverio Stranges; Soumya Swaminathan; Rafael Tabarés-Seisdedos; Fentaw Tadese; Bemnet A Tedla; Balewgizie S Tegegne; Abdullah S Terkawi; J S Thakur; Marcello Tonelli; Roman Topor-Madry; Stefanos Tyrovolas; Kingsley N Ukwaja; Olalekan A Uthman; Masoud Vaezghasemi; Tommi Vasankari; Vasiliy V Vlassov; Stein E Vollset; Elisabete Weiderpass; Andrea Werdecker; Joshua Wesana; Ronny Westerman; Yuichiro Yano; Naohiro Yonemoto; Gerald Yonga; Zoubida Zaidi; Zerihun M Zenebe; Ben Zipkin; Christopher J L Murray
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

View more
  1 in total

1.  High triglyceride-glucose index in young adulthood is associated with incident cardiovascular disease and mortality in later life: insight from the CARDIA study.

Authors:  Xinghao Xu; Rihua Huang; Yifen Lin; Yue Guo; Zhenyu Xiong; Xiangbin Zhong; Xiaomin Ye; Miaohong Li; Xiaodong Zhuang; Xinxue Liao
Journal:  Cardiovasc Diabetol       Date:  2022-08-12       Impact factor: 8.949

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.